Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-PSMA-617 plus standard of care versus standard of care in PSMA-positive metastatic hormone-sensitive prostate cancer
NL-OMON60067Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Nov 2021
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in prostate cancer (PCa) comparing 177Lu-PSMA-617 plus standard of care with Standard of care (2 arms). Primary endpoint: Radiographic progression-free survival. Started Nov 2021; status: active, not recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON60067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60067.